Compare · ENGN vs GILD
ENGN vs GILD
Side-by-side comparison of enGene Therapeutics Inc. (ENGN) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENGN and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $169.23B, about 1315.7x ENGN ($128.6M).
- Over the past year, ENGN is down 48.2% and GILD is up 26.0% - GILD leads by 74.2 points.
- GILD has been more active in the news (7 items in the past 4 weeks vs 3 for ENGN).
- GILD has more recent analyst coverage (25 ratings vs 23 for ENGN).
- Company
- enGene Therapeutics Inc.
- Gilead Sciences Inc.
- Price
- $1.91-0.52%
- $136.99+0.52%
- Market cap
- $128.6M
- $169.23B
- 1M return
- +8.83%
- +7.69%
- 1Y return
- -48.24%
- +25.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 3
- 7
- Recent ratings
- 23
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ENGN
- enGene Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
- Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
- Amendment: enGene Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update
- enGene Therapeutics downgraded by Morgan Stanley
- SEC Form 4 filed by Director Astley-Sparke Philip
- SEC Form 4 filed by Director Brunk Gerald A
- SEC Form 4 filed by Director Glickman Richard M
- SEC Form 4 filed by Interim Chief Medical Officer Grossman William
- SEC Form 4 filed by Director Hastings Paul J
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention